Arrhythmias & electrophysiologyGuideline or statement
Direct Oral Anticoagulants in Primary and Secondary Prevention of Thrombotic Events: 2026 ACC Scientific Statement
- Scientific statement
Scope
As issued by the authors
Established and emerging indications for DOAC therapy in primary and secondary prevention of thrombotic events: AF, acute and extended VTE treatment, special populations (CKD, liver dysfunction, cancer, obesity, frailty, prior bleeding, valvular heart disease), periprocedural anticoagulation, antithrombotic strategies after stroke, left atrial appendage closure and catheter ablation; drug selection, dosing, duration, bleeding risk and management, drug-drug interactions, adherence, cost barriers
Original publication
Direct Oral Anticoagulants in Primary and Secondary Prevention of Thrombotic Events: 2026 ACC Scientific Statement. J Am Coll Cardiol. Published 30 June 2026. doi:10.1016/j.jacc.2026.05.033
Summarised from the published abstract; every number is checked against it